YL 217
Alternative Names: YL-217Latest Information Update: 29 Jul 2025
At a glance
- Originator MediLink Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 02 Jul 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA, China (IV-infusion) (NCT06859762)
- 25 Apr 2025 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Solid tumors presented at 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Mar 2025 MediLink Therapeutics plans a phase I clinical trial in Solid tumours (Late-stage disease) in US in May 2025 (IV, infusion) (NCT06859762)